<DOC>
	<DOC>NCT00476099</DOC>
	<brief_summary>To evaluate the 1-year efficacy and safety of the fixed combination beclometasone/formoterol pMDI in a twice daily regimen in patients with stable severe COPD.</brief_summary>
	<brief_title>Efficacy and Safety Study of Beclometasone/Formoterol Single Inhaler in Patients With COPD</brief_title>
	<detailed_description>The purpose of this study is to evaluate the long-term efficacy and safety of the fixed combination beclometasone/formoterol pMDI in a twice daily regimen in patients with stable severe COPD. Patients are randomised to receive either beclometasone/formoterol or budesonide/formoterol DPI or formoterol DPI during 48 weeks of treatment.</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Beclomethasone</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<criteria>Clinical diagnosis of COPD (according to GOLD guidelines) FEV1 &gt; or equal 30% and &lt; 50% of predicted normal postbronchodilator (and at least 0.7 L absolute value) COPD symptoms for at least 2 years At least 1 exacerbation requiring medical intervention (oral corticosteroid and/or antibiotic treatment and/or need for a visit to an emergency department and/or hospitalization) within 212 months before screening Current or previous smoker with a cumulative exposure to smoke of more than 20pack year Current or past diagnosis of asthma, or any evidence suggestive of asthma Positive FEV1 reversibility test Clinically significant or unstable concurrent diseases, including clinically significant laboratory abnormalities Acute COPD exacerbation or lower tract infection and/or treatment with oral or injectable corticosteroids and antibiotics in the 2 months before screening or during runin Long term oxygen therapy</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>